Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Ionic Liquid Transdermal Patches of Two Active Ingredients Based on Semi-Ionic Hydrogen Bonding for Rheumatoid Arthritis Treatment

“…Transdermal drug delivery systems (TDDSs) are widely recognized as effective for treating RA because they bypass the gastrointestinal side effects associated with oral administration and their potential to stabilize blood concentrations and enhance bioavailability [ 15 ]. Moreover, TDDSs offer the added advantage of convenience and targeted delivery to specific treatment sites, and transdermal patches are attracting attention owing to their simplicity of preparation and manufacturing ease [ 16 , 17 , 18 , 19 ], but the physiological barrier of the skin limits drug delivery [ 20 , 21 , 22 , 23 ]. Ionic liquids (ILs) can bypass the barrier properties of the outermost layer of the epidermis and diffuse intracellularly through mechanisms [ 24 ].…”

Microneedle-assisted dual delivery of PUMA gene and celastrol for synergistic therapy of rheumatoid arthritis through restoring synovial homeostasis

“…Transdermal delivery systems for RA therapy have received growing attention to overcome the first-pass effect of oral route and increase patient compliance compared with systemic or intra-articular injection [ 29 , 30 ]. Polymeric microneedles (MN) with the advantages of pain-free, non-invasiveness and self-administration has inspired researchers to explore their potential applications in the management of chronic diseases including RA [ 31 ]. Moreover, multiple drugs or nanoformulations could be loaded into an MN patch in separated zones or in a mixed manner to achieve an increased convenience and user-friendliness for combined therapy compared with sequential drug injection [ [32] , [33] , [34] ].…”

The Exploitation of Sodium Deoxycholate-Stabilized Nano-Vesicular Gel for Ameliorating the Antipsychotic Efficiency of Sulpiride

“…The convenience and patient-friendly nature of transdermal drug delivery (TDD) is attributed to aspects such as reduced dose frequency, non-invasive administration and ease of application [13]. These factors contribute to improved patient adherence, particularly in cases of extended periods of treatment, such as in the management of chronic pain [14]. Therefore, the transdermal administration of antipsychotic drugs is a dependable approach to boost medication adherence and reduce the need for numerous doses, hence improving patient compliance.…”